Neurocrine Biosciences
NBIX
466 hedge funds and large institutions have $9.6B invested in Neurocrine Biosciences in 2022 Q3 according to their latest regulatory filings, with 79 funds opening new positions, 161 increasing their positions, 161 reducing their positions, and 44 closing their positions.
80% more first-time investments, than exits
New positions opened: 79 | Existing positions closed: 44
33% more funds holding in top 10
Funds holding in top 10: 9 → 12 (+3)
28% more call options, than puts
Call options by funds: $35.1M | Put options by funds: $27.4M
10% more capital invested
Capital invested by funds: $8.74B → $9.6B (+$859M)
6% more funds holding
Funds holding: 438 → 466 (+28)
0.67% more ownership
Funds ownership: 93.82% → 94.49% (+0.67%)
0% more repeat investments, than reductions
Existing positions increased: 161 | Existing positions reduced: 161
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Los Angeles Capital Management
Los Angeles,
California
|
+$80.4M |
| 2 |
Amundi
Paris,
France
|
+$76.3M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$64.5M |
| 4 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$43.3M |
| 5 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$40.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$253M |
| 2 |
Holocene Advisors
New York
|
-$67.5M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$64.9M |
| 4 |
JP Morgan Chase
New York
|
-$63.6M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$61.9M |
NBIX Hedge Fund Activity: Q3 2022 in Review
466 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q3 2022, worth a combined $9.6B — up 9.8% from $8.74B a quarter earlier.
Buyers outnumbered sellers: 79 funds opened new NBIX positions and 44 closed out — a net gain of 35 holders — while 161 added to existing stakes and 161 trimmed.
The largest buyer was Los Angeles Capital Management, opening a new position worth an estimated $80.4M. The largest seller was T. Rowe Price Associates, cutting an estimated $253M.
- 466 institutional investors held Neurocrine Biosciences (NBIX) as of Q3 2022, up from 438 in Q2 2022.
- Funds reported $9.6B of Neurocrine Biosciences stock for Q3 2022, up 9.8% quarter-over-quarter.
- 79 funds opened new Neurocrine Biosciences positions in Q3 2022 and 44 closed out, a net change of +35 holders.
- The largest Neurocrine Biosciences buyer in Q3 2022 was Los Angeles Capital Management, an estimated $80.4M added.
- The largest Neurocrine Biosciences seller in Q3 2022 was T. Rowe Price Associates, an estimated $253M sold.
Based on aggregated 13F filings for Q3 2022.